Semax
Semax (10mg)
$50USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.229
Reference number
10mg
Lyophilized vial
ACTH fragment analog developed at the Russian Institute of Molecular Genetics. In clinical use in Russia since 1996.
Origin
Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by Ashmarin and colleagues beginning in the 1980s. It is a synthetic analog of the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with a C-terminal Pro-Gly-Pro extension that confers metabolic stability and enhances CNS penetration.
Research Lineage
Semax has been a registered pharmaceutical in Russia since 1996, prescribed as a nasal spray for cerebrovascular conditions and cognitive enhancement. Ashmarin, Levitskaya, and colleagues have published extensively on its neuroprotective and nootropic properties. It is one of the few synthetic peptides with a long track record of clinical use in a major national healthcare system.
Mechanism of Action
Semax has been observed to modulate BDNF (brain-derived neurotrophic factor) expression and activate the TrkB signaling pathway in brain tissue models. It interacts with melanocortin receptors (MC3R, MC4R) in the CNS but its full mechanism of action extends beyond melanocortin signaling. Research has investigated effects on dopaminergic and serotonergic neurotransmission, gene expression in hippocampal neurons, and NGF levels.
Structural Notes
Heptapeptide. Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 analog with C-terminal Pro-Gly-Pro extension). Molecular weight: 813.93 Da.
Key References
Ashmarin IP et al. Neurosci Res Commun. 1995;17(2):93-9.
Levitskaya NG et al. Neurosci Behav Physiol. 2008;38(3):249-54.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.